Characteristics | No AAC, Score = 0, n = 21 | AAC, Score ≥ 1, n = 52 | p |
---|---|---|---|
Age, yrs | 54.4 ± 5.9 | 63.1 ± 8.2 | < 0.01c |
Male, n (%) | 3 (14.3) | 16 (30.8) | 0.24b |
Weight, kg | 77.2 ± 22.8 | 72.5 ± 17.8 | 0.32d |
Height, cm | 163.9 ± 8.6 | 165.4 ± 9.2 | 0.50d |
Erosive arthritis, n (%) | 8 (38.1) | 35 (67.3) | 0.02a |
Positive for RF and/or anti-CCP, n (%) | 17 (81.0) | 44 (84.6) | 0.73b |
Disease duration, mos | 132 ± 107 | 160 ± 108 | 0.25d |
Current prednisolone use (%) | 4 (19.0) | 17 (32.7) | 0.39b |
Current methotrexate use, n (%) | 17 (81.0) | 38 (73.1) | 0.56b |
Current anti-TNF-α use, n (%) | 10 (47.6) | 20 (38.5) | 0.47a |
Rheumatoid nodules, n (%) | 1 (4.8) | 14 (26.9) | 0.05b |
Hypertension, n (%) | 6 (28.6) | 25 (48.1) | 0.13a |
SBP | 127 ± 17 | 130 ± 18 | 0.49c |
DBP | 82 ± 11 | 80 ± 12 | 0.24d |
Current smoker, n (%) | 3 (14.3) | 11 (21.2) | 0.74b |
Current aspirin use, n (%) | 2 (9.5) | 4 (7.7) | 1.00b |
Hypercholesterolemia, n (%) | 6 (28.6) | 19 (36.5) | 0.52a |
Total cholesterol, g/l | 2.0 ± 0.4 | 2.2 ± 0.4 | 0.03c |
LDL, g/l | 1.1 ± 0.3 | 1.3 ± 0.3 | 0.03c |
HDL, g/l | 0.6 ± 0.2 | 0.7 ± 0.1 | 0.34c |
Triglycerides, g/l | 1.1 ± 0.7 | 1.1 ± 0.5 | 0.78d |
Glycemia, g/l | 4.3 ± 0.7 | 4.4 ± 1.0 | 0.92d |
EGFR-MDRD, ml/min | 97.6 ± 23.9 | 98.1 ± 19.6 | 0.93c |
hs-CRP, mg/l | 5.5 ± 8.3 | 4.2 ± 6.5 | 0.79d |
Significant results are indicated in bold face.
↵a Chi-square test.
↵b Fisher’s exact test.
↵c Student t test.
↵d Wilcoxon signed-rank test.
RA: rheumatoid arthritis; AAC: abdominal aorta calcification; RF: rheumatoid factor; CCP: cyclic citrullinated peptide; TNF-α: tumor necrosis factor-α; SBP: systolic blood pressure; DBP: diastolic blood pressure; LDL: low-density lipoprotein; HDL: high-density lipoprotein; EGFR-MDRD: estimated glomerular filtration rate using the Modification of Diet in Renal Disease formula; hs-CRP: high-sensitivity C-reactive protein.